How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 117-125

  Bayman, Neil ^a   Blackhall, Fiona ^a   McCloskey, Paula ^a   Taylor, Paul ^b   Faivre Finn, Corinne ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Concurrent chemoradiotherapy; Dose escalation; Elderly; Inoperable; Non small cell lung cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISTANT METASTASIS; HEALTH CARE QUALITY; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW;

CONCURRENT CHEMORADIOTHERAPY; DOSE-ESCALATION; ELDERLY; INOPERABLE; NON-SMALL CELL LUNG CANCER; RADIOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; QUALITY IMPROVEMENT;

EID: 84892845064     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.017     Document Type: Review

References (96)

1. Lim E., Baldwin D., Beckles M., Duffy J., Entwisle J., Faivre-Finn C., et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010, 65(Suppl. 3):iii1-iii27.
2. National Institute of Health and Clinical Excellence The diagnosis and treatment of lung cancer 2011, guideance.nice.org.uk/cg121.
3. Pallis A.G., Gridelli C., van Meerbeeck J.P., Greillier L., Wedding U., Lacombe D., et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 2010, 21:692-706.
4. Crino L., Weder W., van Meerbeeck J., Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v103-v115.
5. Ramnath N., Dilling T.J., Harris L.J., Kim A.W., Michaud G.C., Balekian A.A., et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143:e314S-e340S.
6. Baas P., Belderbos J.S., van den Heuvel M. Chemoradiation therapy in nonsmall cell lung cancer. Curr Opin Oncol 2011, 23:140-149.
7. Brunelli A., Charloux A., Bolliger C.T., Rocco G., Sculier J.P., Varela G., et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009, 34:17-41.
8. Goldstraw P., Ball D., Jett J.R., Le Chevalier T., Lim E., Nicholson A.G., et al. Non-small-cell lung cancer. Lancet 2011, 378:1727-1740.
9. Okawara G., Mackay J.A., Evans W.K., Ung Y.C. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 2006, 1:377-393.
10. Helbrow J., MacNicoll F., Bayman N., Faivre-Finn C. Concurrent chemoradiotherapy for locally advanced, unresectable non-small cell lung cancer: a UK survey of current practice. Clin Oncol (R Coll Radiol) 2012, 24:e127.
11. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):68-70.
12. Group N-SCLCC Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311:899-909.
13. Auperin A., Le Pechoux C., Pignon J.P., Koning C., Jeremic B., Clamon G., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006, 17:473-483.
14. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L., Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215.
15. Sause W., Kolesar P., Taylor S.I., Johnson D., Livingston R., Komaki R., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000, 117:358-364.
16. Belderbos J., Uitterhoeve L., van Zandwijk N., Belderbos H., Rodrigus P., van de Vaart P., et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007, 43:114-121.
17. Machtay M., Paulus R., Moughan J., Komaki R., Bradley J.E., Choy H., et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 2012, 7:716-722.
18. Fournel P., Robinet G., Thomas P., Souquet P.J., Lena H., Vergnenegre A., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005, 23:5910-5917.
19. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
20. Zatloukal P., Petruzelka L., Zemanova M., Havel L., Janku F., Judas L., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46:87-98.
21. Auperin A., Le Pechoux C., Rolland E., Curran W.J., Furuse K., Fournel P., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-2190.
22. O'Rourke N., Macbeth F. Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. Clin Oncol (R Coll Radiol) 2010, 22:347-355.
23. Curran W.J., Paulus R., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
24. Pijls-Johannesma M., Houben R., Boersma L., Grutters J., Seghers K., Lambin P., et al. High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiother Oncol 2009, 91:443-448.
25. Fernandes A.T., Shen J., Finlay J., Mitra N., Evans T., Stevenson J., et al. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes. Radiother Oncol 2010, 95:178-184.
26. Baumann P., Nyman J., Lax I., Friesland S., Hoyer M., Rehn Ericsson S., et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006, 45:787-795.
27. Zimmermann F.B., Geinitz H., Schill S., Thamm R., Nieder C., Schratzenstaller U., et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 2006, 45:796-801.
28. Lagerwaard F.J., Haasbeek C.J., Smit E.F., Slotman B.J., Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:685-692.
29. Onishi H., Shirato H., Nagata Y., Hiraoka M., Fujino M., Gomi K., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2:S94-S100.
30. Timmerman R., McGarry R., Yiannoutsos C., Papiez L., Tudor K., DeLuca J., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
31. Nyman J., Johansson K.A., Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer - mature results for medically inoperable patients. Lung Cancer 2006, 51:97-103.
32. Baumann P., Nyman J., Hoyer M., Gagliardi G., Lax I., Wennberg B., et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol 2008, 88:359-367.
33. Xia T., Li H., Sun Q., Wang Y., Fan N., Yu Y., et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66:117-125.
34. Cox J.D., Azarnia N., Byhardt R.W., Shin K.H., Emami B., Pajak T.F. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0Gy to 79.2Gy: possible survival benefit with greater than or equal to 69.6Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990, 8:1543-1555.
35. Belderbos J.S., De Jaeger K., Heemsbergen W.D., Seppenwoolde Y., Baas P., Boersma L.J., et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 2003, 66:119-126.
36. Marks L.B., Garst J., Socinski M.A., Sibley G., Blackstock A.W., Herndon J.E., et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 2004, 22:4329-4340.
37. Schild S.E., McGinnis W.L., Graham D., Hillman S., Fitch T.R., Northfelt D., et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 65:1106-1111.
38. Sim S., Rosenzweig K.E., Schindelheim R., Ng K.K., Leibel S.A. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001, 51:660-665.
39. Socinski M.A., Morris D.E., Halle J.S., Moore D.T., Hensing T.A., Limentani S.A., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 2004, 22:4341-4350.
40. Socinski M.A., Rosenman J.G., Halle J., Schell M.J., Lin Y., Russo S., et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001, 92:1213-1223.
41. Wu K.L., Jiang G.L., Liao Y., Qian H., Wang L.J., Fu X.L., et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 2003, 57:1336-1344.
42. Bradley J.D., Moughan J., Graham M.V., Byhardt R., Govindan R., Fowler J., et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010, 77:367-372.
43. Salama J.K., Stinchcombe T.E., Gu L., Wang X., Morano K., Bogart J.A., et al. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys 2011, 81:e269-e274.
44. Socinski M.A., Blackstock A.W., Bogart J.A., Wang X., Munley M., Rosenman J., et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008, 26:2457-2463.
45. Bradley J.D., Paulus R., Komaki R., Masters G.A., Forster K., Schild S.E., et al. A randomised phase III comparison of standard dose (60Gy) v high dose (74Gy) conformal chemo-radiotherapy +/- cetuximab in Stage IIIA/B NSCLC: preliminary findings on radiation dose in RTOG 0617. Proc ASTRO 2011, (abstr LB2).
46. Bradley J.D., Paulus R., Komaki R., Masters G.A., Forster K., Schild S.E., et al. A randomized phase III commparison of standard-dose (60Gy) versus high-dose (74Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer. Results on radiation dose in RTOG 0617. J Clin Oncol 2013, (suppl; abstr 7501).
47. Bayman N.A., Blackhall F., Jain P., Lee L., Thatcher N., Faivre-Finn C. Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. Clin Lung Cancer 2008, 9:92-101.
48. Withers H.R., Taylor J.M., Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146.
49. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997, 350:161-165.
50. Saunders M., Dische S., Barrett A., Harvey A., Griffiths G., Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999, 52:137-148.
51. Mauguen A., Le Pechoux C., Saunders M.I., Schild S.E., Turrisi A.T., Baumann M., et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012, 30:2788-2797.
52. van Baardwijk A., Reymen B., Wanders S., Borger J., Ollers M., Dingemans A.M., et al. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. Eur J Cancer 2012, 48:2339-2346.
53. van Elmpt W., De Ruysscher D., van der Salm A., Lakeman A., van der Stoep J., Emans D., et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012, 104:67-71.
54. Grills I.S., Yan D., Martinez A.A., Vicini F.A., Wong J.W., Kestin L.L. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003, 57:875-890.
55. Lievens Y., Nulens A., Gaber M.A., Defraene G., De Wever W., Stroobants S., et al. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study. Int J Radiat Oncol Biol Phys 2011, 80:306-313.
56. Liu H.H., Wang X., Dong L., Wu Q., Liao Z., Stevens C.W., et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58:1268-1279.
57. Schwarz M., Alber M., Lebesque J.V., Mijnheer B.J., Damen E.M. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005, 62:561-570.
58. Liao Z.X., Komaki R.R., Thames H.D., Liu H.H., Tucker S.L., Mohan R., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:775-781.
59. Jiang Z.Q., Yang K., Komaki R., Wei X., Tucker S.L., Zhuang Y., et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys 2012, 83:332-339.
60. Sejpal S., Komaki R., Tsao A., Chang J.Y., Liao Z., Wei X., et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 2010, 117:3004-3013.
61. Vokes E.E., Herndon J.E., Kelley M.J., Cicchetti M.G., Ramnath N., Neill H., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007, 25:1698-1704.
62. Senan S., Cardenal F., Vansteenkiste J., Stigt J., Akyol F., De Neve W., et al. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol 2011, 22:553-558.
63. Hanna N., Neubauer M., Yiannoutsos C., McGarry R., Arseneau J., Ansari R., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26:5755-5760.
64. Garrido P., Rosell R., Arellano A., Andreu F., Domine M., Perez-Casas A., et al. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study. Lung Cancer 2013, 81:84-90.
65. Berghmans T., Van Houtte P., Paesmans M., Giner V., Lecomte J., Koumakis G., et al. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer 2009, 64:187-193.
66. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005, 23:5883-5891.
67. Gandara D.R., Chansky K., Albain K.S., Leigh B.R., Gaspar L.E., Lara P.N., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003, 21:2004-2010.
68. Barriger R.B., Fakiris A.J., Hanna N., Yu M., Mantravadi P., McGarry R.C. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys 2010, 78:1381-1386.
69. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26:2450-2456.
70. Tsujino K., Kurata T., Yamamoto S., Kawaguchi T., Kubo A., Isa S., et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A Pooled Analysis of the Literature. J Thorac Oncol 2013, 8:1181-1189.
71. Koh P.K., Faivre-Finn C., Blackhall F.H., De Ruysscher D. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev 2012, 38:626-640.
72. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
73. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
74. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
75. Spigel D.R., Hainsworth J.D., Yardley D.A., Raefsky E., Patton J., Peacock N., et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010, 28:43-48.
76. Lu C., Lee J.J., Komaki R., Herbst R.S., Feng L., Evans W.K., et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 2010, 102:859-865.
77. Hoang T., Dahlberg S.E., Schiller J.H., Mehta M.P., Fitzgerald T.J., Belinsky S.A., et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol 2012, 30:616-622.
78. Bradley J., Masters G.A., Hu C., Blumenschein G., Bogart J., Schild S., et al. An intergroup randomized phase III comparison of standard-dose (60Gy) versus high-dose (74Gy) chemoradiotherapy (CRT) +/- cetuximab (cetux) for stage III non-small cell lung cancer (NSCLC): results on cetux from RTOG 0617. WCLC 2013, PL03.05.
79. Owonikoko T.K., Ragin C.C., Belani C.P., Oton A.B., Gooding W.E., Taioli E., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007, 25:5570-5577.
80. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000, 36:1741-1754.
81. Fentiman I.S., Tirelli U., Monfardini S., Schneider M., Festen J., Cognetti F., et al. Cancer in the elderly: why so badly treated. Lancet 1990, 335:1020-1022.
82. De Ruysscher D., Botterweck A., Dirx M., Pijls-Johannesma M., Wanders R., Hochstenbag M., et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009, 20:98-102.
83. Holgersson G., Hoye E., Bergqvist M., Ekman S., Nyman J., Helsing M., et al. Swedish Lung Cancer Radiation Study Group: predictive value of age at diagnosis for radiotherapy response in patients with non-small cell lung cancer. Acta Oncol 2012, 51:759-767.
84. Wanders R., Steevens J., Botterweck A., Dingemans A.M., Reymen B., Baardwijk A., et al. Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study. Eur J Cancer 2011, 47:2691-2697.
85. Firat S., Byhardt R.W., Gore E. The effects of comorbidity and age on RTOG study enrollment in Stage III non-small cell lung cancer patients who are eligible for RTOG studies. Int J Radiat Oncol Biol Phys 2012, 78:1394-1399.
86. Langer C., Scott C., Byhardt R., Movsas B., Sause W., Komaki R., et al. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LA-NSCLC). Lung Cancer 2000, 29:104.
87. Movsas B., Scott C., Sause W., Byhardt R., Komaki R., Cox J., et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999, 45:1143-1149.
88. Werner-Wasik M., Scott C., Cox J.D., Sause W.T., Byhardt R.W., Asbell S., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000, 48:1475-1482.
89. Davidoff A.J., Gardner J.F., Seal B., Edelman M.J. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol 2011, 6:934-941.
90. Langer C.J., Hsu C., Curran W.J., Komaki R., Lee J.S., Byhardt R., et al. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 2002, 21. (abstr 1193).
91. Rocha Lima C.M., Herndon J.E., Kosty M., Clamon G., Green M.R. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002, 94:181-187.
92. Schild S.E., Stella P.J., Geyer S.M., Bonner J.A., McGinnis W.L., Mailliard J.A., et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003, 21:3201-3206.
93. Jalal S.I., Riggs H.D., Melnyk A., Richards D., Agarwala A., Neubauer M., et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 2012, 23:1730-1738.
94. Takigawa N., Kiura K., Segawa Y., Hotta K., Tamaoki A., Tokuda Y., et al. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007. J Thorac Oncol 2011, 6:1087-1091.
95. Palma D.A., Senan S., Tsujino K., Barriger R.B., Rengan R., Moreno M., et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013, 85:444-450.
96. Atagi S., Kawahara M., Yokoyama A., Okamoto H., Yamamoto N., Ohe Y., et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012, 13:671-678.